GlaxoSmithKline (GSK) has secured accelerated approval from the US Food and Drug Administration (FDA) for neladalkib, a new oral treatment for certain lung cancer patients, marking a significant step in the company’s efforts to expand its oncology portfolio. The once-daily medication, marketed under the name Nelkarmi, is intended for individuals with a specific type of non-small-cell lung cancer (NSCLC) who have previously undergone treatment.
The approval, announced in November 2026, follows GSK’s earlier FDA clearance this year of Jideytro (zidesamtinib), another lung cancer therapy. Both drugs were obtained through GSK’s $10.6 billion acquisition of Nuvalent, a Boston-based biotech firm specializing in cancer treatments. Completed in July, the acquisition represents the largest transaction in GSK’s 26-year history and underlines the company’s renewed focus on building a competitive presence in the oncology market.
Since assuming the role of chief executive in January, Luke Miels has steered GSK toward re-establishing its cancer drug business. The company had previously exited the oncology sector in 2014 by selling its cancer portfolio to Novartis as part of a $20 billion asset swap. The recent approvals signal a strategic shift toward providing innovative therapies for cancer patients, a lucrative yet challenging industry sector.
Tony Wood, GSK’s chief scientific officer, highlighted the importance of developing treatments that are both effective and tolerable. He noted that many lung cancer patients tend to be younger and may remain on therapy for extended periods, emphasizing the need for new options that improve quality of life.
Despite the positive regulatory milestones, GSK’s shares experienced a slight decline, closing down 0.6 percent at £18.58 in London trading. The company continues to face intense competition in the oncology field as it seeks to leverage its newly acquired assets and expertise to establish a stronger foothold.
